WO2013057724A1 - Packaging for alitretinoin - Google Patents
Packaging for alitretinoin Download PDFInfo
- Publication number
- WO2013057724A1 WO2013057724A1 PCT/IB2012/055762 IB2012055762W WO2013057724A1 WO 2013057724 A1 WO2013057724 A1 WO 2013057724A1 IB 2012055762 W IB2012055762 W IB 2012055762W WO 2013057724 A1 WO2013057724 A1 WO 2013057724A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alitretinoin
- vacuum
- oxygen absorber
- bag
- oxygen
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
- B65D81/24—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants
- B65D81/26—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants with provision for draining away, or absorbing, or removing by ventilation, fluids, e.g. exuded by contents; Applications of corrosion inhibitors or desiccators
- B65D81/266—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants with provision for draining away, or absorbing, or removing by ventilation, fluids, e.g. exuded by contents; Applications of corrosion inhibitors or desiccators for absorbing gases, e.g. oxygen absorbers or desiccants
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D77/00—Packages formed by enclosing articles or materials in preformed containers, e.g. boxes, cartons, sacks or bags
- B65D77/04—Articles or materials enclosed in two or more containers disposed one within another
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
- B65D81/18—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents providing specific environment for contents, e.g. temperature above or below ambient
- B65D81/20—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents providing specific environment for contents, e.g. temperature above or below ambient under vacuum or superatmospheric pressure, or in a special atmosphere, e.g. of inert gas
- B65D81/2007—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents providing specific environment for contents, e.g. temperature above or below ambient under vacuum or superatmospheric pressure, or in a special atmosphere, e.g. of inert gas under vacuum
- B65D81/2023—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents providing specific environment for contents, e.g. temperature above or below ambient under vacuum or superatmospheric pressure, or in a special atmosphere, e.g. of inert gas under vacuum in a flexible container
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
- B65D81/18—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents providing specific environment for contents, e.g. temperature above or below ambient
- B65D81/20—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents providing specific environment for contents, e.g. temperature above or below ambient under vacuum or superatmospheric pressure, or in a special atmosphere, e.g. of inert gas
- B65D81/2069—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents providing specific environment for contents, e.g. temperature above or below ambient under vacuum or superatmospheric pressure, or in a special atmosphere, e.g. of inert gas in a special atmosphere
- B65D81/2084—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents providing specific environment for contents, e.g. temperature above or below ambient under vacuum or superatmospheric pressure, or in a special atmosphere, e.g. of inert gas in a special atmosphere in a flexible container
Definitions
- the present invention relates to the use of an oxygen absorber and silica gel desiccant in a vacuum-sealed pack for the reduction or prevention of oxidative degradation of alitretinoin.
- Alitretinoin is a first generation retinoid.
- the chemical name of alitretinoin is 9-cis retinoic acid or (2£ , ,4£ , ,6Z,8£)-3,7-dimethyl-9-(2,6,6-trimethyl-l-cyclohexenyl)-2,4,6,8- nonatraenoic acid and the structural formula is as follows:
- U.S. Patent No. 6,007,529 discloses a flexible transparent container for the improved storage of oxygen sensitive parenterally administrable agents that is comprised of an inner primary container that is enclosed in an oxygen impermeable outer envelope with an oxygen absorber capable of consuming all residual oxygen after the outer envelope is sealed.
- PCT Publication No. WO 2006/008651 discloses a package to protect pharmaceuticals, e.g., atorvastatin, which comprises a bottle, a desiccant disposed within the first sub-container, and a self-activated metal based oxygen absorber disposed within the second sub-container.
- U.S. Publication No. 2005/0268573 relates to a method for packaging a sterile article that comprises providing a container; placing the article into the interior of the container; exposing the permeable portion of the container to the exterior environment; and removing the sterilizing gas.
- U.S. Publication No. 2009/0071855 discloses a vacuum-sealed pack comprising an amorphous statin or a pharmaceutical composition thereof and at least one stabilizer, for example, an oxygen absorber, a moisture absorber, or a combination thereof.
- a method for the reduction or prevention of oxidative degradation of alitretinoin using an oxygen absorber and a silica gel desiccant in a vacuum-sealed pack comprising alitretinoin, an oxygen absorber and a silica gel desiccant.
- a vacuum-sealed pack comprising a pharmaceutical composition comprising alitretinoin, an oxygen absorber, and a silica gel desiccant.
- a method for the reduction or prevention of oxidative degradation of alitretinoin comprising an oxygen absorber and a silica gel desiccant in a vacuum-sealed pack.
- a vacuum-sealed pack comprising alitretinoin, an oxygen absorber and a silica gel desiccant.
- a vacuum-sealed pack which includes a pharmaceutical composition comprising alitretinoin, an oxygen absorber, and a silica gel desiccant.
- vacuum-sealed pack refers to a low density polyethylene (LDPE) bag that is twisted and tied with a plastic fastener under nitrogen. This bag is packed into a middle bag of polyester/LDPE, a vacuum is applied to the middle bag, and it is heat sealed. The sealed middle bag is packed into a polyester/alumi- num/polyester/LDPE bag. Vacuum is applied to the polyester/aluminum/polyester/LDPE bag and it is then heat sealed.
- LDPE low density polyethylene
- oxygen absorber is a material capable of absorbing oxygen from the surrounding atmosphere.
- Oxygen absorbers can be inorganic metal based oxygen absorbers; ascorbic acid based absorbers; enzymatic absorbers; or polymer based oxygen absorbers. Examples of specific oxygen absorbers include, but are not limited to, O-Buster®, FreshPax®, Ageless®, StabilOx® or ZPTJTM.
- Stability studies of alitretinoin were conducted by loading alitretinoin samples at various stability conditions, for example, at 25 ⁇ 2°C/60 ⁇ 5% relative humidity (RH) and 40 ⁇ 2°C/75 ⁇ 5% RH in the absence or presence of an oxygen absorber and a silica desiccant for 1 month, 2 months, 3 months, or 6 months.
- the stability studies were performed on a stability incubator (for accelerated stability studies, Hotpack was used and for real time stability studies, NuAire® was used).
- the degradation products were identified using an Agilent® 1 100 series HPLC system.
- the “pharmaceutical composition”, as used herein, includes both capsule and gel forms.
- Example 1 Stability Studies of Alitretinoin at 25 ⁇ 2°C/60 ⁇ 5%RH and 40 ⁇ 2°C/75 ⁇ 5% RH in the Absence of Oxygen Absorber and Silica Gel Desiccant
- Alitretinoin was packed in a LDPE bag.
- the bag was twisted and tied with a plastic fastener under nitrogen.
- the LDPE bag was placed into a middle bag of polyester/LDPE and vacuum was applied to the middle bag and then it was heat sealed.
- the sealed middle bag was packed into a polyester/aluminum/polyester/LDPE bag.
- Example 2 Stability Studies of Alitretinoin at 25 ⁇ 2°C/60 ⁇ 5 % RH in the Presence of Oxygen Absorber (Stabilox® and Silica Gel Desiccant
- Alitretinoin was packed in a LDPE bag.
- the bag was twisted and tied with a plastic fastener under nitrogen.
- the LDPE bag was placed into a middle bag of polyester/LDPE along with an oxygen absorber. A vacuum was applied to the middle bag and then it was heat sealed.
- the sealed middle bag was packed into a
- polyester/aluminum/polyester/LDPE bag along with silica gel as a desiccant. Vacuum was applied to this bag and it was then heat sealed. The vacuum-sealed pack was loaded on stability at 25 ⁇ 2°C and 60 ⁇ 5% RH. The results are presented in Table 2.
- Alitretinoin was packed in a LDPE bag; the bag was twisted and tied with a plastic fastener under nitrogen. It was placed into a middle bag of polyester/LDPE along with an oxygen absorber. Vacuum was applied to the middle bag and then it was heat sealed. This sealed middle bag was packed into a polyester/aluminum/polyester/LDPE bag along with silica gel as a desiccant. Vacuum was applied to this bag and then it was heat sealed. The vacuum-sealed pack was loaded on stability at 40 ⁇ 2°C and 75 ⁇ 5% RH. The results are presented in Table 3.
Abstract
The present invention relates to the use of an oxygen absorber and silica gel desiccant in a vacuum-sealed pack for the reduction or prevention of oxidative degradation of alitretinoin.
Description
PACKAGING FOR ALITRE TINOIN
Field of the Invention
The present invention relates to the use of an oxygen absorber and silica gel desiccant in a vacuum-sealed pack for the reduction or prevention of oxidative degradation of alitretinoin.
Background of the Invention
Alitretinoin is a first generation retinoid. The chemical name of alitretinoin is 9-cis retinoic acid or (2£,,4£,,6Z,8£)-3,7-dimethyl-9-(2,6,6-trimethyl-l-cyclohexenyl)-2,4,6,8- nonatraenoic acid and the structural formula is as follows:
Formula I
The European Public Assessment Report (EPAR) scientific discussion document on alitretinoin published by the European Medicines Agency (accessible at
http://www.ema.europa.eu/docs/en GB/document library/EPAR -
Scientific Discussion/¾iuman/'000279/WC500038707.pdf, page 2) discloses that in alitretinoin, decomposition was extensive in the presence of oxygen giving rise to a large number of impurities. Drug degradation often limits shelf life or may render a drug unmarketable. Therefore, such drugs are required to be stored in the absence of oxygen or under a condition that the oxygen content is very small. To achieve this, nitrogen may be filled into a container or a package. However, once such container is opened or the package is unwrapped, air flows in and the quality cannot be prevented from deterioration.
In the pharmaceutical industry, there have been reports of using oxygen absorbers to stabilize drugs. For example, Japanese Patent No. JP 59- 176247 discloses a method for preventing the decomposition of water-soluble azunole of Formula II
Formula II
by packing and sealing it in a glass impermeable container together with a deoxidant. U.S. Patent No. 6,007,529 discloses a flexible transparent container for the improved storage of oxygen sensitive parenterally administrable agents that is comprised of an inner primary container that is enclosed in an oxygen impermeable outer envelope with an oxygen absorber capable of consuming all residual oxygen after the outer envelope is sealed.
PCT Publication No. WO 2006/008651 discloses a package to protect pharmaceuticals, e.g., atorvastatin, which comprises a bottle, a desiccant disposed within the first sub-container, and a self-activated metal based oxygen absorber disposed within the second sub-container. U.S. Publication No. 2005/0268573 relates to a method for packaging a sterile article that comprises providing a container; placing the article into the interior of the container; exposing the permeable portion of the container to the exterior environment; and removing the sterilizing gas. U.S. Publication No. 2009/0071855 discloses a vacuum-sealed pack comprising an amorphous statin or a pharmaceutical composition thereof and at least one stabilizer, for example, an oxygen absorber, a moisture absorber, or a combination thereof.
There is a need to provide a packaging system for alitretinoin for the reduction or prevention of its oxidative degradation.
Summary of the Invention
In one aspect, there is provided a method for the reduction or prevention of oxidative degradation of alitretinoin using an oxygen absorber and a silica gel desiccant in a vacuum-sealed pack.
In another aspect, there is provided a vacuum-sealed pack comprising alitretinoin, an oxygen absorber and a silica gel desiccant.
In yet another aspect, there is provided a vacuum-sealed pack comprising a pharmaceutical composition comprising alitretinoin, an oxygen absorber, and a silica gel desiccant.
Detailed Description of the Invention
In one aspect, there is provided a method for the reduction or prevention of oxidative degradation of alitretinoin comprising an oxygen absorber and a silica gel desiccant in a vacuum-sealed pack.
In another aspect, there is provided a vacuum-sealed pack comprising alitretinoin, an oxygen absorber and a silica gel desiccant.
In yet another aspect, there is provided a vacuum-sealed pack which includes a pharmaceutical composition comprising alitretinoin, an oxygen absorber, and a silica gel desiccant.
The term "vacuum-sealed pack", as used herein, refers to a low density polyethylene (LDPE) bag that is twisted and tied with a plastic fastener under nitrogen. This bag is packed into a middle bag of polyester/LDPE, a vacuum is applied to the middle bag, and it is heat sealed. The sealed middle bag is packed into a polyester/alumi- num/polyester/LDPE bag. Vacuum is applied to the polyester/aluminum/polyester/LDPE bag and it is then heat sealed.
The term "oxygen absorber", as used herein, is a material capable of absorbing oxygen from the surrounding atmosphere. Oxygen absorbers can be inorganic metal based oxygen absorbers; ascorbic acid based absorbers; enzymatic absorbers; or polymer based oxygen absorbers. Examples of specific oxygen absorbers include, but are not limited to, O-Buster®, FreshPax®, Ageless®, StabilOx® or ZPTJ™.
Stability studies of alitretinoin were conducted by loading alitretinoin samples at various stability conditions, for example, at 25±2°C/60±5% relative humidity (RH) and 40±2°C/75±5% RH in the absence or presence of an oxygen absorber and a silica desiccant for 1 month, 2 months, 3 months, or 6 months. The stability studies were performed on a stability incubator (for accelerated stability studies, Hotpack was used and
for real time stability studies, NuAire® was used). The degradation products were identified using an Agilent® 1 100 series HPLC system.
The "pharmaceutical composition", as used herein, includes both capsule and gel forms.
While the present invention has been described in terms of its specific
embodiments, certain modifications and equivalents will be apparent to those skilled in the art and are included within the scope of the present invention. Examples are provided to illustrate particular aspects of the disclosure and do not limit the scope of the present invention.
EXAMPLES
Example 1 : Stability Studies of Alitretinoin at 25±2°C/60±5%RH and 40±2°C/75±5% RH in the Absence of Oxygen Absorber and Silica Gel Desiccant
Alitretinoin was packed in a LDPE bag. The bag was twisted and tied with a plastic fastener under nitrogen. The LDPE bag was placed into a middle bag of polyester/LDPE and vacuum was applied to the middle bag and then it was heat sealed. The sealed middle bag was packed into a polyester/aluminum/polyester/LDPE bag.
Vacuum was applied to this bag and then it was heat sealed. The vacuum-sealed pack was loaded on stability at stations 40±2°C and 75±5% RH (accelerated) and 25±2°C and 60±5% RH. The results are presented in Table 1.
Table 1:
Impurities Initial 2M/25±2°C/60±5% lM/40±2°C/75±5%
RH RH
0.026 0.123 0.176
4-Oxo-alitretinoin 0.024 0.156 0.170
0.012 0.063 0.052
0.007 0.1 13 0.161
4-Hydroxy alitretinoin 0.009 0.156 0.160
0.001 0.058 0.048
0.021 0.268 0.362
5,6-Epoxy alitretinoin
0.049 0.376 0.380
0.018 0.142 0.1 14
0.403 0.892 1.146
Total related substances 0.41 1 1.128 1.181
0.351 0.537 0.403
Example 2: Stability Studies of Alitretinoin at 25±2°C/60±5 % RH in the Presence of Oxygen Absorber (Stabilox® and Silica Gel Desiccant
Alitretinoin was packed in a LDPE bag. The bag was twisted and tied with a plastic fastener under nitrogen. The LDPE bag was placed into a middle bag of polyester/LDPE along with an oxygen absorber. A vacuum was applied to the middle bag and then it was heat sealed. The sealed middle bag was packed into a
polyester/aluminum/polyester/LDPE bag along with silica gel as a desiccant. Vacuum was applied to this bag and it was then heat sealed. The vacuum-sealed pack was loaded on stability at 25±2°C and 60±5% RH. The results are presented in Table 2.
Table 2:
*ND = not detected
Example 3: Stability Studies of Alitretinoin at 40±2°C/75±5%RH in the Presence of Oxygen Absorber (Stabilox® and Silica Gel Desiccant
Alitretinoin was packed in a LDPE bag; the bag was twisted and tied with a plastic fastener under nitrogen. It was placed into a middle bag of polyester/LDPE along with an oxygen absorber. Vacuum was applied to the middle bag and then it was heat sealed.
This sealed middle bag was packed into a polyester/aluminum/polyester/LDPE bag along with silica gel as a desiccant. Vacuum was applied to this bag and then it was heat sealed. The vacuum-sealed pack was loaded on stability at 40±2°C and 75±5% RH. The results are presented in Table 3.
Table 3:
*ND = not detected
From the results tabulated in Table 2 and Table 3, it has been concluded that in the presence of an oxygen absorber and a silica gel desiccant, alitretinoin showed no increase in oxidative impurities.
Claims
1. A method for the reduction or prevention of oxidative degradation of alitretinoin comprising an oxygen absorber and a silica gel desiccant in a vacuum-sealed pack.
2. A vacuum-sealed pack comprising alitretinoin, an oxygen absorber and a silica gel desiccant.
3. A vacuum-sealed pack comprising a pharmaceutical composition which includes alitretinoin, an oxygen absorber, and a silica gel desiccant.
4. The vacuum-sealed pack of claims 1, 2, or 3, wherein the oxygen absorber is an inorganic metal based oxygen absorber; an ascorbic acid based absorber; an enzymatic absorber; or a polymer based oxygen absorber.
5. The vacuum-sealed pack of claims 1, 2, or 3, wherein the oxygen absorber is StabilOx®.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/351,928 US20140262858A1 (en) | 2011-10-21 | 2012-10-19 | Packaging for alitretinoin |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN3019/DEL/2011 | 2011-10-21 | ||
| IN3019DE2011 | 2011-10-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2013057724A1 true WO2013057724A1 (en) | 2013-04-25 |
Family
ID=47278918
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IB2012/055762 WO2013057724A1 (en) | 2011-10-21 | 2012-10-19 | Packaging for alitretinoin |
Country Status (2)
| Country | Link |
|---|---|
| US (1) | US20140262858A1 (en) |
| WO (1) | WO2013057724A1 (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59176247A (en) | 1983-03-28 | 1984-10-05 | Taiyo Yakuhin Kogyo Kk | Method for preventing decomposition of water-soluble azunole |
| US6007529A (en) | 1996-04-10 | 1999-12-28 | Pharmacia & Upjohn Ab | Containers for parenteral fluids |
| US20050268573A1 (en) | 2004-01-20 | 2005-12-08 | Avantec Vascular Corporation | Package of sensitive articles |
| WO2006008651A1 (en) | 2004-07-16 | 2006-01-26 | Pfizer Products Inc. | Pharmaceutical package for simultaneously maintaining low moisture and low oxygen levels |
| WO2009024946A1 (en) * | 2007-08-21 | 2009-02-26 | Ranbaxy Laboratories Limited | A packaging kit comprising a light, moisture and/or oxygen sensitive drug |
| US20090071855A1 (en) | 2007-09-14 | 2009-03-19 | Bahuguna Sumit | Packaging for amorphous statins and compositions thereof |
| US20090249747A1 (en) * | 2008-04-02 | 2009-10-08 | Sumitomo Electric Industries, Ltd. | Method of Packaging Compound Semiconductor Substrates |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5414049A (en) * | 1993-06-01 | 1995-05-09 | Howmedica Inc. | Non-oxidizing polymeric medical implant |
| BR112012015615A2 (en) * | 2009-12-24 | 2018-05-29 | Bm Gol Pty Ltd | single use containers and their uses |
-
2012
- 2012-10-19 US US14/351,928 patent/US20140262858A1/en not_active Abandoned
- 2012-10-19 WO PCT/IB2012/055762 patent/WO2013057724A1/en active Application Filing
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59176247A (en) | 1983-03-28 | 1984-10-05 | Taiyo Yakuhin Kogyo Kk | Method for preventing decomposition of water-soluble azunole |
| US6007529A (en) | 1996-04-10 | 1999-12-28 | Pharmacia & Upjohn Ab | Containers for parenteral fluids |
| US20050268573A1 (en) | 2004-01-20 | 2005-12-08 | Avantec Vascular Corporation | Package of sensitive articles |
| WO2006008651A1 (en) | 2004-07-16 | 2006-01-26 | Pfizer Products Inc. | Pharmaceutical package for simultaneously maintaining low moisture and low oxygen levels |
| WO2009024946A1 (en) * | 2007-08-21 | 2009-02-26 | Ranbaxy Laboratories Limited | A packaging kit comprising a light, moisture and/or oxygen sensitive drug |
| US20090071855A1 (en) | 2007-09-14 | 2009-03-19 | Bahuguna Sumit | Packaging for amorphous statins and compositions thereof |
| US20090249747A1 (en) * | 2008-04-02 | 2009-10-08 | Sumitomo Electric Industries, Ltd. | Method of Packaging Compound Semiconductor Substrates |
Also Published As
| Publication number | Publication date |
|---|---|
| US20140262858A1 (en) | 2014-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20020132359A1 (en) | Dispensing unit for oxygen-sensitive drugs | |
| US8029842B2 (en) | Low water activity oxygen scavenger and methods of using | |
| US20070163917A1 (en) | Package and device for simultaneously maintaining low moisture and low oxygen levels | |
| FR2839497A1 (en) | PACKAGE FOR USE IN TRANSPORTING STERILE OBJECTS OR IN STERELIZING | |
| US9908682B2 (en) | Storage of ampoules containing pharmaceutical formulations using a sealed container comprising an oxygen scavenger | |
| KR20070100720A (en) | Oxygen-impervious packaging with optional oxygen scavenger, stabilized thyroid hormone compositions and methods for storing thyroid hormone pharmaceutical compositions | |
| EP2836458B1 (en) | Oxygen-releasing inserts | |
| CN103842265A (en) | Improved flat packaging of petri dishes for prolonged preservation and method of producing the same | |
| WO2013057724A1 (en) | Packaging for alitretinoin | |
| JP2017531604A (en) | Method for packaging an elastomer part and its packaging | |
| US20080317859A1 (en) | Stabilization of Testosterone Within Transdermal Devices | |
| CN205633649U (en) | High sealed pharmaceutical packaging case structure | |
| RU130139U1 (en) | WATERPROOF PACKAGING FOR SEMICONDUCTOR PLATES | |
| JP2016147695A (en) | Packaging bag | |
| JP2022148904A (en) | Liquid preparation and preparation container containing liquid preparation | |
| WO2020257134A1 (en) | Protection of oxygen sensitive compounds | |
| KR20230159703A (en) | Liquid-containing combination container, container set, and method of manufacturing liquid-containing container | |
| JP2023098491A (en) | Liquid-filled combination container, container set, and liquid-filled container manufacturing method | |
| JPS63167738A (en) | Gas-replacement packaging of fish and shellfishes | |
| NZ222810A (en) | Package containing oxygen-sensitive food and oxygen scavenger | |
| WO2012164315A2 (en) | Active oxygen scavenging system |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12795071 Country of ref document: EP Kind code of ref document: A1 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 14351928 Country of ref document: US |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 12795071 Country of ref document: EP Kind code of ref document: A1 |